gene therapy firm’s stock faces pivotal year By Investing.com
Precigen, Inc. (NASDAQ:), a biotechnology company specializing in gene and cell therapies with a market capitalization of $276 million, is navigating a critical juncture in its development as it focuses on bringing its lead candidate to market while streamlining operations. According to InvestingPro data, the company’s stock has shown significant volatility, with a beta of 1.71, reflecting the dynamic nature of its development stage. The company’s strategic pivot towards PRGN-2012, a potential treatment for recurrent respiratory papillomatosis (RRP), marks a significant shift in its approach to value creation and pipeline management.
Strategic Focus on PRGN-2012
Precigen’s primary focus has shifted decisively to PRGN-2012, a gene…
